Random Walk stumbles across active ETFs
Burton Malkiel is updating his iconic book to reflect the rise of exchange-traded funds. But what will he say about products like smart beta that…
- October 20, 2014 September 13, 2019
- 09:54
Burton Malkiel is updating his iconic book to reflect the rise of exchange-traded funds. But what will he say about products like smart beta that…
A new research paper addresses the critics of leveraged exchange-traded funds (ETFs) by pointing out that they ignore the effects of capital flows on ETF…
Star power can make a lot of money in Hollywood, but it can be toxic in the investment industry. That message came across loud and…
Download the PDF to read more Big data is not just a buzzword anymore. Businesses across the world are taking a deep dive into all…
As Canadian institutional investors embrace fixed income exchange-traded funds, they need to be aware of where the liquidity is coming from - and what it…
Plan sponsor panel: Rethinking risk across pension portfolios
Some risks can't be eliminated - but they can be managed.
The California Public Employees’ Retirement System's (CalPERS) decision to dump its hedge fund program has set off a discussion about the importance of cost, simplicity…
Plan sponsor panel on the rise of risk factors among DB plans.
Having been well schooled in the meaning of the term “black swan event” over the last decade, investors are already peeking around corners and looking…
At the symposium, Zurock shared the collective experiences of one or two large groups who have made the decision to implement a mandatory generic policy.
France Gauthier, manager of drug plan management at Medavie Blue Cross, discussed the important role of generics in the private plan landscape and, specifically, in…
Over the last few years, plan sponsors have received a break on drug spending through falling generic drug prices and medicines going off-patent. But, with…